{"id":"W4225678126","doi":"10.1093/ehjcvp/pvac023","title":"Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; McMaster University; Population Health Research Institute; Hamilton Health Sciences; Hamilton General Hospital","funders":"Janssen Pharmaceuticals; Idorsia Pharmaceuticals; KU Leuven; Sanofi; Bayer HealthCare; Bristol-Myers Squibb; CSL Behring; Merck; Bayer; Servier; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Rivaroxaban; Aspirin; Coronary artery disease; Internal medicine; Myocardial infarction; Stroke (engine); Randomized controlled trial; Hazard ratio; Confidence interval; Warfarin; Surgery; Cardiology; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009197541,0.0001806793,0.0004655162,0.00006983046,0.0004177655,0.00005003617,0.000238497,0.00000828616,0.00009414608],"category_scores_gemma":[0.000005964229,0.00007271572,0.0003046868,0.0002206201,0.0001153132,0.0001292868,0.0001442236,0.0002124283,4.150039e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001806441,"about_ca_system_score_gemma":0.00009428465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001159776,"about_ca_topic_score_gemma":0.000004809634,"domain_scores_codex":[0.9972762,0.001308135,0.0003443528,0.0001913692,0.0007185236,0.0001614046],"domain_scores_gemma":[0.9991565,0.00007025053,0.0002235887,0.0004128239,0.00007210694,0.00006475601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03574307,0.0002294074,0.9527876,0.00003818563,0.00196365,0.00008661043,0.0003432166,0.001561147,0.0003028072,0.000003346894,0.00004833452,0.006892621],"study_design_scores_gemma":[0.1029713,0.001867064,0.890658,0.00006797384,0.0004441212,0.00007267705,0.00005055555,0.00005517672,0.00005523868,8.639665e-7,0.003667062,0.00008997982],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935118,0.002102462,0.00002018786,0.001716763,0.0001834033,0.002422262,0.000008320047,0.00000788095,0.00002694045],"genre_scores_gemma":[0.9988477,0.0003143246,0.00001616077,0.0002192779,0.0001771202,0.00001295791,0.000007142598,0.0000385327,0.0003667867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06722822,"threshold_uncertainty_score":0.3213157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06342639653316291,"score_gpt":0.3316879162528724,"score_spread":0.2682615197197095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}